 GSK is facing a new competitor for its respiratory syncytial virus RSV vaccine after Moderna published data for its alternative, according to analysts at Barclays. Modernas efficacy data looks in line with GSKs, and, while there are still a lot of questions to answer timing of market entry, detailed data, duration of effect, we think GSKs underperformance today reflects consideration of a three-player vs. 